Emmanuel Dulac
Chief Executive Officer at Igyxos SA
Emmanuel Dulac active positions
| Companies | Position | Start | End |
|---|---|---|---|
Igyxos SA
 Igyxos SA Pharmaceuticals: MajorHealth Technology Igyxos SA engages in the development of an innovative medical and pharmaceutical technologies in the field of human fertility. It is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds. The company was founded by Marie-Christine Maurel and is headquartered in Nouzilly, France. | Chief Executive Officer | 01/06/2023 | - |
Career history of Emmanuel Dulac
Former positions of Emmanuel Dulac
| Companies | Position | Start | End |
|---|---|---|---|
| ZEALAND PHARMA A/S | Chief Executive Officer | 22/04/2019 | 30/03/2022 |
| President | 22/04/2019 | 30/03/2022 | |
| SHIRE | Corporate Officer/Principal | 01/06/2014 | 01/08/2016 |
| NOVARTIS AG | Corporate Officer/Principal | 01/02/2006 | 01/05/2014 |
| SANOFI | Corporate Officer/Principal | 01/10/1994 | 01/08/2003 |
| PROTEOSTASIS THERAPEUTICS, INC. | Director/Board Member | 05/02/2019 | - |
| Independent Dir/Board Member | 05/02/2019 | - | |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 19/08/2016 | - |
Training of Emmanuel Dulac
| ESSEC Business School | Masters Business Admin |
Statistics
International
| France | 5 |
| United States | 3 |
| Ireland | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Chief Executive Officer | 2 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| SANOFI | Commercial Services |
| NOVARTIS AG | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| Private companies | 4 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Université de Paris XI Paris Sud | Consumer Services |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Igyxos SA
Igyxos SA Pharmaceuticals: MajorHealth Technology Igyxos SA engages in the development of an innovative medical and pharmaceutical technologies in the field of human fertility. It is involved in all phases of development, from the discovery of promising targets to the identification of potential lead compounds. The company was founded by Marie-Christine Maurel and is headquartered in Nouzilly, France. | Health Technology |
- Stock Market
- Insiders
- Emmanuel Dulac
- Experience
